LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Spinal Fluid Marker Strongly Predicts Mental Decline

By LabMedica International staff writers
Posted on 19 Mar 2012
Print article
A novel marker of Alzheimer's disease (AD) can predict how rapidly a patient's memory and other mental abilities will decline after the disorder is diagnosed.

Higher levels of the marker, visinin-like protein 1 (VILIP-1), in the cerebrospinal fluid (CSF) of Alzheimer's patients have been linked to a more rapid mental decline in the years that followed.

Scientists at Washington University School of Medicine (St. Louis, MO, USA) studied 60 individuals with a clinical diagnosis of very mild or mild AD and measuring baseline CSF protein levels of VILIP-1, Tau, phosphorylated Tau-181 (p-tau181), and amyloid-beta 1–42 (Aβ42), and these were followed longitudinally for an average of 2.6 years.

Baseline CSF VILIP-1 and VILIP-1/Aβ42 levels predicted rates of future decline in the clinical dementia rating and global composite scores over the follow-up period. Individuals with CSF VILIP-1 equal to or greater than 560 pg/mL progressed much more rapidly than individuals with lower values. CSF tau, p-tau181, tau/ Aβ42, and p-tau181/ Aβ42 also predicted more rapid cognitive decline overtime. Scientists think VILIP-1 serves as a calcium sensor in brain cells. It is released into the cerebrospinal fluid when the cells are injured. CSF samples were analyzed for total tau, p-tau181, Aβ42 using Innotest, (Innogenetics, Ghent, Belgium), and CSF Aβ40 by an enzyme-linked immunosorbent assay. CSF samples were analyzed for VILIP-1 by Erenna, a microparticle-based immunoassay (Singulex, CA, USA).

Rawan Tarawneh, MD, the lead author of the study, said "VILIP-1 appears to be a strong indicator of ongoing injury to brain cells as a result of Alzheimer's disease. That could be very useful in predicting the course of the disease and in evaluating new treatments in clinical trials. These results are intriguing, but we need a larger study to fully understand how the insights provided by VILIP-1 compare to those we can gain from other markers.” The study was published online on February 22, 2012, in the journal Neurology.

Related Links:
Washington University School of Medicine
Innogenetics
Singulex


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Coagulation Analyzer
CS-2400

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.